Prescient Therapeutics CEO Transition Announcement

Prescient Therapeutics Limited (ASX:PTX) has announced that Mr. Steven Yatomi-Clarke, the Managing Director and Chief Executive Officer, will be stepping down in early 2025 to pursue a new appointment. Mr. Yatomi-Clarke intends to remain in his position until the end of February 2025, while the company conducts a search for a new CEO.

Prescient Chair and CEO's Comments on CEO Transition

Prescient Chair, Steve Engle, expressed deep appreciation for Steven's outstanding leadership and strategic vision in building the company and an international R&D team over the last eight years. He highlighted Mr. Yatomi-Clarke's significant contributions to the development of PTX-100 oncology candidate and the establishment of Prescient as a recognized leader in novel cancer therapies. Mr. Yatomi-Clarke also shared his pride in the company's achievements during his tenure and expressed excitement about its prospects and upcoming milestones.

Summary of Prescient Therapeutics CEO Transition

Prescient Therapeutics (ASX:PTX) has announced the upcoming transition of its CEO, Mr. Steven Yatomi-Clarke, in early 2025. The company will conduct a search for a new CEO to continue its momentum. Mr. Yatomi-Clarke, while stepping down, will remain available as a consultant to provide ongoing assistance. Additionally, he has been selected as the inaugural CEO of Aurora Biosynthetics, a private company spearheading the development of an RNA ecosystem in Australia. The announcement reflects Prescient's commitment to seamless leadership transition and continued pursuit of its corporate goals and initiatives.